Evidence map›Paper›PMID 35239034›Full record

ArticleEJNMMI radiopharmacy and chemistry2022

A proof-of-concept study on the use of a fluorescein-based

Hugo Helbert, Emily M Ploeg, Douwe F Samplonius, Simon N Blok, Ines F Antunes, Verena I Böhmer, Gert Luurtsema, Rudi A J O Dierckx, Ben L Feringa, Philip H Elsinga and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hugo HelbertStratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747, Groningen, The Netherlands.
Emily M PloegDepartment of Surgery, Translational Surgical Oncology, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Douwe F SamploniusDepartment of Surgery, Translational Surgical Oncology, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Simon N BlokDepartment of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Ines F AntunesDepartment of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Verena I BöhmerStratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747, Groningen, The Netherlands.
Gert LuurtsemaDepartment of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Rudi A J O DierckxDepartment of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Ben L FeringaStratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747, Groningen, The Netherlands.
Philip H ElsingaDepartment of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. p.h.elsinga@umcg.nl.
Wiktor SzymanskiDepartment of Radiology, Medical Imaging Center, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. w.szymanski@umcg.nl.ORCID http://orcid.org/0000-0002-9754-9248
Wijnand HelfrichDepartment of Surgery, Translational Surgical Oncology, University of Groningen, UMC Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
University Medical Center Groningen · NLUniversity of Groningen · NL

Funding

KWF Kankerbestrijding 11464Nederlandse Organisatie voor Wetenschappelijk Onderzoek NWO-CW VIDI grant 723.014.001
6 · The paper itself

Abstract

backgroundPretargeted immuno-PET tumor imaging has emerged as a valuable diagnostic strategy that combines the high specificity of antibody-antigen interaction with the high signal and image resolution offered by short-lived PET isotopes, while reducing the irradiation dose caused by traditional

resultsA copper(I)-catalysed click reaction-based radiolabeling protocol was developed for the synthesis of fluorescein-derived molecule [

conclusionA versatile pretargeting platform for PET imaging, which combines bispecific antibodies and a fluorescein-based

Indexed as

[18F]Fluorescein[18F]TPFBispecific antibodyImmunoPETPretargeting

Identifiers

PMID35239034
PMCPMC8894538
OpenAlexW4214826426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.